Novartis' Upcoming Clinical Trial Results Could Shape Long-Term Growth Outlook
Investors are closely watching Novartis as it prepares for three major clinical trial results later this year that could significantly impact its long-term growth trajectory. The outcomes of these trials, involving cardiovascular treatment pelacarsen, multiple sclerosis candidate remibrutinib, and genetic disease therapy del-desiran, will be critical in supporting the company's premium valuation amid looming patent expirations.
Topics: growth outlook Novartis pipeline trial results